Tuesday, 27 October 2020


Onyx rejects $10 bn takeover bid by Amgen

02 July 2013 | News | By BioSpectrum Bureau

Onyx rejected a $10 billion takeover offer from Amgen as too low but still is considering selling itself

Onyx rejected a $10 billion takeover offer from Amgen as too low but still is considering selling itself

Singapore: Onyx Pharmaceuticals rejected a $10 billion takeover offer from Amgen as too low but still is considering selling itself. Onyx said Amgen's cash offer of $120 a share significantly undervalued its prospects.

Onyx said in a statement it was "actively exploring" a merger partner, and that it had hired financial advisor Centerview Partners to contact potential buyers. The San Francisco-based company cited "expressions of interest" from Amgen and other unnamed third parties.


Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account